Over time, obese patients lose roughly 12% of their body weight on Wegovy (semaglutide) and about 18% on Zepbound (tirzepatide, which targets GLP-1 and another gut hormone, GIP.) Diana Thiara, MD, medical director of the UCSF Weight Management Program, says the results can be amazing and life-changing for people with obesity, a condition linked to a host of health risks
Slower clinician response times (5 to 7 days vs
[17] Meta-analyses of L-carnitine-the formulations primary shuttle for long-chain fatty acids-show modest but statistically significant reductions in body weight and body-mass index in adults with overweight or obesity
For personalized advice and more information, contact Tulsi Wellness Club today
Comparative genetics of longevity and cancer: Insights from long-lived rodents
It contains semaglutide , the same active ingredient as Ozempic, but Wegovy is specifically approved for weight management